TAKERO SHINDO

Last Updated :2026/07/03

Affiliations, Positions
Research Institute for Radiation Biology and Medicine, Associate Professor
E-mail
takerohiroshima-u.ac.jptakeroskuhp.kyoto-u.ac.jp
Other Contact Details
1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8553 Japan, Japan
TEL : (+81)81-82-257-5 FAX : (+81)81-82-256-7
Self-introduction
I am originally from Hiroshima, and I came back to Hiroshima for the first time in 30 years in 2023. I work in the field of Hematology as a clinician, and I also conduct research focusing on transplant immunology and HTLV-1/ATL. Whereas I am surprised at many things back in Hiroshima after a long time, I do my best to give back to my hometown.

Basic Information

Major Professional Backgrounds

  • 1997/05/01, 1998/05/31, Kyoto University Hospital, Internal Medicine, Resident
  • 1998/06/01, 2000/05/31, Shinko Hospital, Internal Medicine, Clinical Fellow
  • 2000/06/01, 2002/03/31, Nagahama City Hospital, Department of Hematology/Oncology, Clinical Fellow
  • 2007/04/01, 2008/12/31, Kansai Electric Power Hospital, Department of Hematology, Clinical Fellow
  • 2025/04/01, Hiroshima University Research Institute for Radiation Biology and Medicine, Department of Hematology/Oncology, Associate Professor
  • 2023/08/01, 2025/03/31, Hiroshima University Research Institute for Radiation Biology and Medicine, Next Generation Development of Genome and Cellular Therapy Program, Professor, Collaborative Research Laboratory
  • 2016/11/01, 2023/07/31, Kyoto University Hospital, Department of Hematology and Oncology, Assistant Professor
  • 2012/08/01, 2016/10/31, Saga University School of Medicine, Hematology/Respiratory Medicine and Oncology, Assistant Professor
  • 2010/08/01, 2012/07/31, University of Miami Sylvester Comprehensive Cancer Center, Adult Stem Cell Transplant Program, Post-doctoral research fellow
  • 2009/02/01, 2010/07/31, Fred Hutchinson Cancer Research Center, Clinical Research Division, Post-doctoral research fellow

Educational Backgrounds

  • Kyoto University Graduate School of Medicine, School of Medicine, Hematology/Oncology, Japan, 2002/04, 2006/03
  • Kyoto University, School of Medicine, Japan, 1991/04, 1997/03

Academic Degrees

  • Ph.D., Kyoto University

In Charge of Primary Major Programs

  • Medicine

Research Fields

  • Medicine,dentistry, and pharmacy;Clinical internal medicine;Hematology
  • Medicine,dentistry, and pharmacy;Basic medicine;Immunology

Research Keywords

  • HTLV-1
  • Histocompatibility antigen
  • Tumor immunology
  • Transplant immunology

Affiliated Academic Societies

  • The Japan Society of Transfusion Medicine and Cell Therapy, 2024/11
    Related URL

Educational Activity

Course in Charge

  1. 2026, Undergraduate Education, Year, Clinical diagnosis and treatment I
  2. 2026, Undergraduate Education, Year, Clinical diagnosis and treatment II
  3. 2026, Undergraduate Education, Year, Systemic Disease Control
  4. 2026, Undergraduate Education, Intensive, Practice for medical research
  5. 2026, Undergraduate Education, Intensive, Practice of Medicine I
  6. 2026, Undergraduate Education, Intensive, Practice of Medicine II
  7. 2026, Undergraduate Education, First Semester, Internal Medicine II
  8. 2026, Graduate Education (Master's Program) , Second Semester, General Clinical Medicine and Dentistry
  9. 2026, Graduate Education (Doctoral Program) , 1Term, Principles of Oncology

Research Activities

Academic Papers

  1. ★, MEK inhibitors selectively suppress alloreactivity and graft-versus-host disease in a memory stage-dependent manner., Blood, 121(23), 4617-4626, 2013
  2. ★, Growth and differentiation advantages of CD4+OX40+ T cells from allogeneic hematopoietic stem cell transplantation recipients., Biol Blood Marrow Transplant, 3(10), 1176-1184, 200803
  3. Altered homeostasis of CD4+ memory T cells in allogeneic hematopoietic stem cell transplant recipients: chronic graft-versus-host disease enhances T cell differentiation and exhausts central memory T cell pool., Biol Blood Marrow Transplant, 13(10), 1176-1184, 200710
  4. Platinum TALEN-mediated nonviral gene editing facilitates clinical-scale production of cancer antigen-reactive T cells., Cytotherapy, 2026
  5. ★, Real-world treatments and outcomes of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a Japanese claims analysis., Int J Hematol, 2026
  6. ★, Long-read KIR genotyping reveals donor KIR/HLA polymorphisms linked to posttransplant relapse in T-cell malignancies., Blood Advances, 2026
  7. ★, Control of immune response in iPSC-based allogeneic cell therapy for Parkinson's disease, Cell Stem Cell, 32(9), 1346-1355, 2025
  8. The Intersection of Lynch Syndrome and Hematological Malignancies: A Rare Case Report, eJHaem, 2025
  9. ★, Cross-organ hierarchy of HLA molecular mismatches in donor-specific antibody development in solid organ transplantations, Cell Reports Medicine, 6(6), 102153, 20250530
  10. ★, Phase I/II trial of iPSC-derived dopaminergic cells for Parkinson's disease, Nature, 641, 971-977, 20250416
  11. ★, Upregulation of YY1/EZH2 and MLH1 as Therapeutic Targets for Adult T-Cell Leukemia/Lymphoma, Cancer Science, 20250512
  12. Significant detrimental impact of pre-transplant mogamulizumab in allogeneic hematopoietic cell transplantation, Bone Marrow Transplantation, 60(4), 552-554, 2025
  13. Impact of HLA Epitope Matching on Outcomes in Haploidentical HSCT With Distinct GVHD Prophylaxes, Transplantation, 109(7), 1241-1250, 20250214
  14. Trametinib Suppresses the Stimulated T Cells Through G1 Arrest and Apoptosis, EUROPEAN JOURNAL OF IMMUNOLOGY, 55(2), 202502
    Link to Paper Search Results by DOI
  15. Individual HLAs affect survival after allogeneic stem cell transplantation in adult T-cell leukemia/lymphoma, HLA, 103(6), e15555, 2024
  16. Long-term efficacy and safety of tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: Final analysis of phase IIb results, Haematologica, 109(10), 3357-3362, 2024
  17. ★, Co-existence of oligoclonal and polyclonal HTLV-1-positive T cells with presentation of acute-type adult T-cell leukemia-lymphoma successfully treated by ultraviolet B phototherapy and etretinate, J Eur Acad Dermatol Venereol, 39(4), e297-e299, 20240808
  18. Acalabrutinib and obinutuzumab for chronic lymphocytic leukemia complicated with peripheral neuropathy, Cureus, 16(11), e74703, 2024
  19. KIR3DL1-HLA-Bw status in CML is associated with achievement of TFR: the POKSTIC trial, a multicenter observational study, Blood Neoplasia, 1(1), 100001-100001, 202403
  20. Successful treatment of severe splenic lymphoma-associated hemophagocytic syndrome by splenectomy and subsequent chemotherapy: A case report, ONCOLOGY LETTERS, 27(5), 202405
    Link to Paper Search Results by DOI
  21. ★, Tucidinostat restores CCR4 expression in adult T-cell leukemia/lymphoma, Haematologica, 109(3), 1007-1009, 2023
  22. 18F-FDG-PET/MRI of the mandible for numb chin syndrome due to acute myeloid leukemia, Neurology and Clinical Neuroscience, 12(2), 121-122, 20230828
  23. Genetic manipulation resulting in decreased donor chondroitin sulfate synthesis mitigates hepatic GVHD via suppression of T cell activity, Scientific Reports, 13(1), 13098, 20230811
  24. ★, Epitope Mismatch at HLA-DRB1 Associates with Reduced Relapse Risk in Cord Blood Transplantation for Standard-Risk Hematologic Malignancy, Transplantation and Cellular Therapy, 29(6), 347.e1-347.e11, 202306
  25. Regression of intestinal diffuse large B cell lymphoma after treatment with vedolizumab in a patient with Crohn's disease, European Journal of Cancer, 176, 189-192, 202211
  26. Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results, Haematologica, 108(3), 811-821, 20221006
  27. TCR repertoire reflects remission status in lenalidomide-treated myeloma, 1485-1485, 202210
  28. ★, Dual inhibition of the MEK/ERK and PI3K/AKT pathways prevents pulmonary GVHD suppressing perivenulitis and bronchiolitis, Blood Advances, 7(1), 106-121, 20220425
  29. Favorable HLA Polymorphisms are Associated with Lower Molecular Relapse after Tyrosine Kinase Discontinuation in Patients with Chronic Myeloid Leukemia, Indian Journal of Hematology and Blood Transfusion, 20220418
  30. Impact of HLA Epitope Matching on Outcomes After Unrelated Bone Marrow Transplantation, Frontiers in Immunology, 13, 811733-811733, 20220303
  31. Development of a novel Indium-111 radiolabeled mogamulizumab targeting CCR4 for imaging adult T-cell leukemia/lymphoma in vivo, Annals of Nuclear Medicine, 36(3), 319-326, 202203
  32. Small B-cell neoplasm responding to ibrutinib after 17 years of cold agglutinin disease symptom., Rinsho Ketsueki, 62(12), 1678-1683, 202112
  33. ★, Pharmacological MEK inhibition promotes polyclonal T-cell reconstitution and suppresses xenogeneic GVHD, Cellular Immunology, 367, 104410-104410, 202109
  34. ★, KIR3DL1 Allotype-Dependent Modulation of NK Cell Immunity against Chronic Myeloid Leukemia, ImmunoHorizons, 5(8), 687-702, 20210801
  35. ★, Early Elevation of Complement Factor Ba Is a Predictive Biomarker for Transplant-Associated Thrombotic Microangiopathy, Frontiers in Immunology, 12, 695037-695037, 20210713
  36. Next-generation sequencing in two cases of de novo acute basophilic leukaemia, Journal of Cellular and Molecular Medicine, 25(14), 7095-7099, 202107
  37. ★, T-cell chimerism prior to graft-versus-host disease, European Journal of Cardio-Thoracic Surgery, 20210125
  38. Primary hepatic lymphoma as other iatrogenic immunodeficiency-related lymphoproliferative disorders: a case report and review of the literature, Modern Rheumatology Case Reports, 5(1), 172-177, 20210102
  39. HLA Polymorphisms Are Associated with Treatment-Free Remission Following Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia, Molecular Cancer Therapeutics, 20(1), 142-149, 202101
  40. Donor-dominant one-way matching of human leukocyte antigen-A/B/DR alleles predicts graft-versus-host disease following living donor liver transplantation, Hepatology Research, 51(1), 135-148, 202101
  41. GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma, Bone Marrow Transplantation, 56(1), 155-166, 202101
  42. Secondary failure of platelet recovery in patients treated with high-dose thiotepa and busulfan followed by autologous stem cell transplantation, International Journal of Hematology, 112(5), 609-613, 202011
  43. Upper Gastrointestinal Langerhans Cell Histiocytosis: A Report of 2 Adult Cases and a Literature Review, International Journal of Surgical Pathology, 29(5), 106689692096456-106689692096456, 20201009
  44. ★, The MEK Inhibitor Trametinib Suppresses Major Histocompatibility Antigen-mismatched Rejection Following Pancreatic Islet Transplantation, Transplantation Direct, 6(9), e591-e591, 202009
  45. The prognostic impact of FLT3-ITD, NPM1 and CEBPa in cytogenetically intermediate-risk AML after first relapse, International Journal of Hematology, 112(2), 200-209, 202008
  46. Allelic polymorphisms of KIRs and antitumor immunity against chronic myeloid leukemia, Immunological Medicine, 1-8, 20200725
  47. Drug monitoring for mycophenolic acid in graft-versus-host disease prophylaxis in cord blood transplantation, British Journal of Clinical Pharmacology, 20200530
  48. ★, Reconstitution of NK cells expressing KIR3DL1 is associated with reduced NK cell activity and relapse of CML after allogeneic hematopoietic stem cell transplantation, International Journal of Hematology, 111(5), 733-738, 202005
  49. ★, Phosphorylated ERK1/2 in CD4 T cells is associated with acute GVHD in allogeneic hematopoietic stem cell transplantation, Blood Advances, 4(4), 667-671, 20200225
  50. Role of cancer immunology in chronic myelogenous leukemia, Leukemia Research, 88, 106273-106273, 202001
  51. Hepatitis-associated Aplastic Anemia With Rapid Progression of Liver Fibrosis Due to Repeated Hepatitis., Internal Medicine, 59(8), 1035-1040, 201912
  52. Allelic polymorphisms of KIRs and HLAs predict favorable responses to tyrosine kinase inhibitors in CML, 78, IS9-3, 201909
  53. ★, Trametinib Attenuates Delayed Rejection and Preserves Thymic Function in Rat Lung Transplantation, American Journal of Respiratory Cell and Molecular Biology, 61(3), 355-366, 201909
  54. Clinical impact of the CONUT score and mogamulizumab in adult T cell leukemia/kymphoma., Ann Hematol, 98(2), 465-471, 201902
  55. Epstein-Barr virus-related diffuse large B cell lymphoma in mogamulizumab-treated adult T cell leukemia with incomplete T cell reconstitution., Int J Hematol, 109(2), 221-227, 201902
  56. Phosphorylation of ERK1/2 in CD4+ T cells is associated with GVHD after allo-HSCT, Rinsho Ketsueki, 59(9), 1524-1524, 201809
  57. Human BM-MSC derived extracellular vesicles modulate hematopoietic cells in GVHD mice, 59(9), 1515-1515, 201809
  58. Monitoring of citrulline and diamine oxidase levels as biomarkers for intestinal mucositis during early-phase of hematopoietic cell transplantation., Blood Cell Ther, 201808
  59. ★, Allelic polymorphisms of KIRs and HLAs predict favorable responses to tyrosine kinase inhibitors in CML, Cancer Immunology Research, 6(6), 745-754, 20180601
  60. Outcome of patients with relapsed aggressive adult T-cell leukemia-lymphoma: clinical effectiveness of anti-CCR4 antibody and allogeneic hematopoietic stem cell transplantation., Haematologica, 103(5), e211-e214, 201805
  61. ★, Deep sequencing of the T cell receptor visualizes reconstitution of T cell immunity in mogamulizumab-treated adult T cell leukemia, OncoImmunology, 7(3), e1405204, 20180304
  62. ★, Graft-Versus-Host Disease Amelioration by Human Bone Marrow Mesenchymal Stromal/Stem Cell-Derived Extracellular Vesicles Is Associated with Peripheral Preservation of Naive T Cell Populations, Stem Cells, 36(3), 434-445, 201803
  63. Tocilizumab for severe cytokine-release syndrome after haploidentical donor transplantation in a patient with refractory Epstein-Barr virus-positive diffuse large B-cell lymphoma, Hematological Oncology, 36(1), 324-327, 20180201
  64. Successful autologous hematopoietic stem cell transplantation followed by bortezomib maintenance in a patient with relapsed CD138-low multiple solitary plasmacytomas harboring a 17p deletion, Internal Medicine, 57(6), 855-860, 2018
  65. Polymorphisms and avidity of KIR3DL1 and HLA-B alleles predict response to TKI in CML, Rinsho Ketsueki, 58(9), 1502-1502, 201709
  66. Autopsy case of systemic EBV-positive T-cell lymphoma of childhood with marked hepatomegaly in a middle-aged man, PATHOLOGY INTERNATIONAL, 67(8), 431-433, 201708
  67. Elderly Patients With Chronic Myeloid Leukemia Benefit From a Dasatinib Dose as Low as 20 mg, CLINICAL LYMPHOMA MYELOMA AND LEUKEMIA, 17(6), 370-374, 201706
  68. 5q-syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10), INTERNATIONAL JOURNAL OF HEMATOLOGY, 105(5), 692-696, 201705
  69. Chronic myelogenous leukemia and NK cell immunity, Rinsho Ketsueki, 58(4), 381-388, 201704
  70. Persistent Gastrointestinal Angiodysplasia in Heyde's Syndrome after Aortic Valve Replacement, INTERNAL MEDICINE, 56(18), 2431-2433, 2017
  71. ★, Altered homeostasis of CD4(+) memory T cells in allogeneic hematopoietic stem cell transplant recipients: Chronic graft-versus-host disease enhances T cell differentiation and exhausts central memory T cell pool, BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 13(10), 1176-1184, 200710
  72. Friend or foe? Mogamulizumab in allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma, Stem Cell Investigation, 2016(70), 20161001
  73. Subdural hematoma associated with dasatinib and intrathecal methotrexate treatment in Ph+ALL, Rinsho Ketsueki, 57(9), 1721-1721, 201609
  74. PET-CT in lvmphoma-associated hemophagocytic syndrome in an Epstein-Barr virus-positive patient, Rinsho Ketsueki, 57(9), 1743-1743, 201609
  75. ★, Effector Regulatory T Cells Reflect the Equilibrium between Antitumor Immunity and Autoimmunity in Adult T-cell Leukemia, CANCER IMMUNOLOGY RESEARCH, 4(8), 644-649, 201608
  76. ★, The MEK inhibitor trametinib separates murine Graft-versus-Host Disease from Graft-versus-Tumor Effects, JCI Insight, 1(10), e86331, 201607
  77. Domino-Style Cerebral Bleeding in a Patient With Immune Thrombocytopenic Purpura, JAMA NEUROLOGY, 73(4), 474-475, 201604
  78. Rituximab-induced Acute Thrombocytopenia in High Tumor Burden Follicular Lymphoma, INTERNAL MEDICINE, 55(15), 2061-2064, 2016
  79. Subdural Hematoma Associated with Dasatinib and Intrathecal Methotrexate Treatment in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia, INTERNAL MEDICINE, 55(18), 2703-2706, 201609
  80. Coexistence of ALK-anaplastic large cell lymphoma and CD4+T cell large granular lymphocytic leukemia, ANNALS OF HEMATOLOGY, 94(3), 539-540, 201503
  81. Brainstem Encephalitis with anti-ganglioside antibody associated with mogamulizumab treatment, Rinsho Ketsueki, 55(9), 1489-1489, 201409
  82. T-Cell Characterization Using Multicolor Flow Cytometry After Allogeneic Hematopoietic Stem-Cell Transplantation, JOURNAL OF CLINICAL ONCOLOGY, 32(17), 1859-1860, 201406
  83. Therapeutic management in cardiac lymphoma, LEUKEMIA AND LYMPHOMA, 55(5), 1215-1217, 201405
  84. 10 cases of Mogamulizumab treatment for Adult T cell leukemia in Saga prefecture, Rinsho Ketsueki, 54(9), 1438-1438, 201309
  85. ★, MEK inhibitors selectively suppress alloreactivity and graft-versus-host disease in a memory stage-dependent manner., Blood, 121(23), 4617-4626, 201306
  86. ★, Growth and differentiation advantages of CD4(+)OX40(+) T cells from allogeneic hematopoietic stem cell transplantation recipients, BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 14(3), 268-281, 200803
  87. Nonsecretory primary plasma cell leukemia successfully treated with VAD and MP therapy., Rinsho Ketsueki, 43(2), 107-111, 200202
  88. Clinical impact of the CONUT score in patients with multiple myeloma, Annals of hematology, 99(1), 113-119, 201911
  89. Allelic polymorphism of KIRs in chronic myeloid leukemia, MHC, 25(3), 187-195, 201812
  90. Immune defects in multiple myeloma., Nippon Rinsho, 73(1), 52-56, 201501
  91. 電子カルテと輸血管理システムの連携による輸血後鉄過剰症モニタリングの運用とその課題, 60(1), 12-17, 201401
  92. Management of transfusional iron overload., Japanese J of Transfusion and Cell Therapy, 59(1), 73-78, 201301

Invited Lecture, Oral Presentation, Poster Presentation

  1. With a "big" help from clinical flow cytometry to advance your hematology, Takero Shindo, The 87th annual meeting of the Japanese Society of Hematology, 2025/10/12, With Invitation, Japanese, The Japanese Society of Hematology, Kobe, Japan
  2. Antibody-mediated rejection depending on immunogenicity of HLA eplets, Takero Shindo, The 61st annual meeting of the Japanese Society of Transplantation, 2025/10/10, With Invitation, Japanese, The Japanese Society of Transplantation, Nagoya, Japan
  3. Solid organ transplants from a clinical hematologist: HLA eplets and antibody-mediated rejection, Takero Shindo, The 61st annual meeting of the Japanese Society of transplantation, 2025/10/10, With Invitation, Japanese, The Japanese Society of Transplantation, Nagoya, Japan
  4. Tumor immunology and transplant immunology through KIR alleles and HLA eplets, Takero Shindo, 2025/06/07, With Invitation, Japanese
  5. Efficacy of pirtobrutinib in ibrutinib-intolerant advanced-stage mantle cell lymphoma: a case report., Nao Yoshida, Tetsumi Yoshida, Suzuka Nakatani, Ren Chishaki, Taro Edahiro, Sayaka Sugihara, Takero Shindo, Tatsuo Ichinohe., The 87th annual meeting of the Japanese Society of Hematology, 2025/10/11, Without Invitation, Japanese, The Japanese Society of Hematology, Kobe, Japan
  6. Axi-cel enabled CR of post-transplant lymphoproliferative disorder and cessation of tacrolimus., Taro Edahiro, Takero Shindo, Kentaro Ide, Yuka Tanaka, Nao Yoshida, Suzuka Nakatani, Ren Chisyaki, Tetsumi Yoshida, Sayaka Sugihara, Tatsuo Ichinohe., The 87th annual meeting of the Japanese Society of Hematology, 2025/10/11, Without Invitation, Japanese, The Japanese Society of Hematology, Kobe, Japan
  7. Tumor inflammation-associated neurotoxicity during CAR-T cell therapy for CNS relapse in DLBCL., Kenjiro Hino, Taro Edahiro, Hiroshi Ureshino, Suzuka Nakatani, Nao Yoshida, Ren Chishaki, Tetsumi Yoshida, Takero Shindo, Takuya Nunomura, Takeshi Okatani, Tsuyoshi Muta, Michiko Kida, Miki Kido, Takuo Ito, Tatsuo Ichinohe., The 87th annual meeting of the Japanese Society of Hematology, 2025/10/10, Without Invitation, Japanese, The Japanese Society of Hematology, Kobe, Japan
  8. NIX-mediated inhibition of mitophagy leads to activation and differentiation of T lymphocytes., Takumu Tsuchida, Takashi Ushiki, Hajime Ishiguro, Miho Yoshiike, Hikaru Kanome, Tatsuya Suwabe, Takayuki Katagiri, Kyoko Fuse, Yasuhiko Shibasaki, Takero Shindo, Keiichi Inoue, Tomotake Kanki, Hirohito Sone, Masayoshi Masuko., The 87th annual meeting of the Japanese Society of Hematology, 2025/10/10, Without Invitation, Japanese
  9. Transplants and HLA/KIR, Takero Shindo, 2025/03/15, Without Invitation, Japanese
  10. Gamma-delta-type CD8 T cells were associated with the progression of hepatitis-associated aplastic anemia., Nao Yoshida, Takero Shindo*, Suzuka Nakatani, Ren Chishaki, Taro Edahiro, Tetsumi Yoshida, Tatsuo Ichinohe., The 15th Japanese Society of Hematology (JSH) International Symposium, 2025/05, Without Invitation, English, The Japanese Society of Hematology, Karatsu
  11. Two cases that developed severe localized cytokine releasing syndrome after CAR-T therapy, Nao Yoshida, Taro Edahiro, Suzuka Nakatani, Ren Chishaki, Tetsumi Yoshida, Takero Shindo, Tatsuo Ichinohe, 2025/03, Without Invitation, Japanese
  12. Acalabrutinib and Obinutuzumab improved peripheral neuropathy and CLL with anti-ganglioside antibody, Taro Edahiro, Hiroshi Ureshino, Nao Yoshida, Suzuka Nakatani, Ren Chishaki, Tetsumi Yoshida, Sayaka Sugihara, Takero Shindo, Tatsuo Ichinohe, 2024/10/12, Without Invitation, Japanese
  13. Tirabrutinib for CNS relapse in primary vitreoretinal lymphoma, Nao Yoshida, Hiroshi Ureshino, Suzuka Nakatani, Ren Chishaki, Taro Edahiro, Tetsumi Yoshida, Takero Shindo, Tatsuo Ichinohe, 2024/10/12, Without Invitation, Japanese
  14. Sutilimab for RB resistant cold agglutinin disease-associated lymphoproliferative disorder, Ren Chishaki, Hiroshi Ureshino, Nao Yoshida, Suzuka Nakatani, Taro Edahiro, Tetsumi Yoshida, Sayaka Sugihara, Takero Shindo, Tatsuo Ichinohe, 2024/10/12, Without Invitation, Japanese
  15. Functional analysis of NY-ESO-1-reactive genome-edited T cells manufactured using Platinum TALEN, Kayo Toishigawa, Hiroyuki Sato, Saori Fukunaga, Kenta Magoori, Taro Edahiro, Hiroshi Ureshino, Takero Shindo, Ryuji Suzuki, Tatsuo Ichinohe, 2024/10/11, Without Invitation, Japanese
  16. Donor NK cell education by KIR3DL1 and HLA-B associates with reduced relapse in unrelated bone marrow transplantation for adult T-cell leukemia., Mari Morita-Fujita; Takero Shindo; Shuji Kawaguchi; Kiyotaka Izumi; Yuichi Inadomi; Masakazu Shimizu; Ai Murano; Akiyo Morinibu; Meiko Takahashi; Junya Kanda; Taro Tsujimura; Takuya Yamamoto; Koji Kato; Hidenori Tanaka; Nobuyuki Nakano; Tetsuya Eto; Yasuhiko Miyazaki; Kazunori Imada; Youko Suehiro; Toshiro Kawakita; Tatsuo Ichinohe; Takahiro Fukuda; Makoto Onizuka; Yoshiko Atsuta; Fumihiko Matsuda; Akifumi Takaori-Kondo, The 65th Annual Meeting of the American Society of Hematology, 2023/12/11, Without Invitation, English
  17. A new era with newly developed therapeutic reagents against relapsed/resistant ATL, Takero Shindo, 2023/11/10
  18. Association analysis of KIR alleles and relapses in unrelated-BMT for adult T-cell leukemia, Mari Morita-Fujita; Takero Shindo; Shuji Kawaguchi; Masakazu Shimizu; Yuichi Inadomi; Ai Murano; Akiyo Morinibu; Junya Kanda; Meiko Takahashi; Taro Tsujimura; Takuya Yamamoto; Koji Kato; Hidenori Tanaka; Nobuaki Nakano; Tetsuya Eto; Yasuhiko MIyzaki; Kazunori Imada; Youko Suehiro; Toshiro Kawakita; Tatsuo Ichinohe; Takahiro Fukuda; Makoto Onizuka; Yoshiko Atsuta; Fumihiko Matsuda; Akifumi Takaori, 2023/10/15
  19. Polyclonal innunoglobulin recovery confers better outcome despite MRD in ASCT-treated myeloma, Chika Tokuda; Takero Shindo; Chisaki Mizumoto; Akifumi Takaori-Kondo, 2023/10/14
  20. Significance of YY1/EZH2/MLH1 axis for progression of adult T-cell leukemia (ATL), Takuya Shimizu; Takero Shindo; Akira Watanabe; Akifumi Takaori-Kondo, 2023/10/14
  21. Skewed TCR is associated with long-term remission in lenalidomide-treated MM, Hiroshi Ureshino; Takero Shindo; Yukio Namamura; Kazutaka Kitaura; Haruhiko Sano; Atsujiro Nishioka; Tadashu Shin-I; Ryuji Suzuki; Shinya Kimura, 2023/10/14
  22. Compensatory activation of multiple kinases determines sensitivity of CML cells to MEK inhibitors, Huong Thi Ngo; Takero Shindo; Arisa Kato; Takuya Shimizu; Seiji Okada; Takeshi Inukai; Shinya Kimura; Akifumi Takaori-Kondo, 2022/10/14
  23. Post-treatment tonsillar TLG/MTV in FDG-PET/CT may predict relapse-free survival of DLBCL, Takuya Shimizu; Takero Shindo; Sho Koyasu; Yuji Nakamoto; Akifumi Takaori-Kondo, 2022/10/14
  24. Impact of Human Leukocyte Antigen Epitope Matching on Outcomes after Unrelated Bone Marrow Transplantation., Makoto Iwasaki; Junya Kanda; Hidenori Tanaka; Takero Shindo; Noriko Doki; Takahiro Fukuda; Yukiyasu Ozawa; Tetsuya Eto; Naoyuki Uchida; Yuta Katayama; Keisuke Kataoka; Makoto Onizuka; Yoshinobu Kanda; Tatsuo Ichinohe; Yoshiko Atsuta; Satoko Morishima, The 63rd Annual Meeting of the American Society of Hematology, 2021/12
  25. Dual Inhibition of the MEK/ERK and PI3K/AKT Pathways Prevents Pulmonary Graft-Versus-Host Disease through Suppression of Arteriovenous Inflammation and Bronchiolitis., The 63rd Annual Meeting of the American Society of Hematology, 2021/12
  26. The MEK inhibitor cobimetinib suppresses lung GVHD through inhibition of B cells and monocytes., Muranushi H; Shindo T; Ngo TH; Gochi F; Yoshizawa A; Chen-Yoshikawa TF; Takaori-Kondo A, 2021/09/25
  27. KIR3DL1 allotype-dependent modulation of NK cell immunity against chronic myeloid leukemia., Izumi K; Shindo T; Ngo TH; Nakayama-Hosoya K; Akahane K; Tamai M; Nguyen TT; Kawana-Tachikawa A; Inukai T; Takaori-Kondo A, 2021/09/24
  28. HLA polymorphisms is associated with treatment-free remission following TKI discontinuation., Ureshino H; Shindo T; Kimura S, The 82nd annual meeting of the Japanese Society of Hematology, 2020/10
  29. The impact of individual HLAs on survival after allo-HSCT from HLA-matched donors for ATL patients., Morishima S; Shindo T; Utsunomiya A; Ishida T; Fukuda T; Nakano N; Kawakita T; Eto T; Suehiro Y; Sawayama Y; Miyamoto T; Ichinohe T; Atsuta Y; Yoshimitsu M; Kato K, The 82nd annual meeting of the Japanese Society of Hematology, 2020/10
  30. Graft-Versus-Host Disease Free, Relapse-Free Survival in Allogeneic Stem Cell Transplantation for Adult T-cell Leukemia/Lymphoma Provides a Novel Donor Selection Paradigm., Muranushi H; Shindo T; Hishizawa M; Tokunaga M; Wake A; Nakano N; Eto T; Hidaka M; Suehiro Y; Miyamoto T; Uchida N; Moriuchi Y; Miyazaki Y; Fukuda T; Ichinohe T; Atsuta Y; Kato K; ATL Working; Group of; Japanese; Society for; Hematopoietic Cell Transplantation, The 61st Annual Meeting of the American Society of Hematology (ASH), 2019/12/08
  31. The MEK inhibitor trametinib enhances diverse T cell reconstitution with suppressing xenogeneic GVHD., Itamura H; Muranishi H; Shindo T; Kitaura K; Okada S; Shin-I T; Suzuki R; Takaori-Kondo A; Kimura S, The 61st Annual Meeting of the American Society of Hematology (ASH), 2019/12/08
  32. Allelic polymorphisms of KIRs and HLAs predict favorable responses to tyrosine kinase inhibitors in CML., The 78th Annual Meeting of the Japanese Cancer Association (International Symposium), 2019/09/28
  33. Phosphorylation of ERK1/2 in CD4+ T cells is associated with acute GVHD in allogeneic hematopoietic stem cell transplantation, Takero Shindo; Hidekazu Itamura; Satoshi Yoshioka; Takayuki Ishikawa; Shinya Kimura, The 80th annual meeting of the Japanese Society of Hematology, 2018/10/12
  34. Human Bone Marrow Mesenchymal Stromal/Stem Cell-Derived Extracellular Vesicles Ameliorate Graft-Versus-Host Disease-Related Manifestations., Fujii S; Miura Y; Fujishiro A; Shindo T; Shimazu Y; Hirai H; Takaori-Kondo A; Ichinohe T; Maekawa T, The 59th annual meeting of the American Society of Hematology, 2017/12
  35. TCR Repertoire, Effector Regulatory T-cells and KIR Genotyping Uncover Immunological Dynamics in Mogamulizumab-treated ATL, Takero Shindo; Yasushi Kusunoki; Kazutaka Kitaura; Hiroyoshi Nishikawa; Nobukazu Watanabe; Hiroshi Ureshino; Masaharu Miyahara; Tatsuro Watanabe; Eizaburo Sueoka; Luis J Espinoza; Akiyoshi Takami; Tatsuo Ichinohe; Ryuji Suzuki; Hidenori Tanaka; Hiroh Saji; Shinya Kimura, International Conference of Human Retrovirology HTLV and related viruses, 2017
  36. The MEK inhibitor trametinib selectively suppresses GVHD, while sparing GVT and antiviral immunity., Takero Shindo, The 7th Japanese Society of Hematology (JSH) International Symposium, 2016/05/14
  37. The MEK inhibitor trametinib selectively suppresses GVHD, while sparing GVT effects., Itamura H; Shindo T; Tawara I; Kariya R; Okada S; Komanduri KV, Biol Blood Marrow Transplant, 2015/02
  38. Trametinib selectively inhibits alloreactivity while sparing virus-specific T cells., Wieder ED; Kolonias D; Benjamin CL; Shindo T; Kim TK; Levy RB; Komanduri KV, Biol Blood Marrow Transplant, 2014/02
  39. MEK Inhibitors Selectively Suppress Human T Cell Alloreactivity in a Memory Stage-Dependent Manner., Shindo T; Kim TK; Benjamin CL; LevyRB; Wieder ED; Komanduri KV, The 53rd annual meeting of the American Society of Hematology, 2011/12
  40. The Elevated Ratio of Peripheral Blood CD27−CD4+ T Cells in Patients Received Allogeneic Stem Cell Transplantation Implies Altered T Cell Homeostasis., Fukunaga A; Ishikawa T; Shindo T; Takao S; Hori T; Uchiyama T, The 47th annual meeting of the American Society of Hematology, 2005/12
  41. Interleukin-2-Producing CD4+OX40+ T Cell as a Target for the Treatment of Chronic Graft-Versus-Host-Disease., Shindo T; Ishikawa T; Fukunaga A; Hori T; Uchiyama T, The 47th annual meeting of the American Society of Hematology, 2005/12

Awards

  1. 2025/02, Uehara Memorial Foundation Grant-in-aid for Medical Research, Uehara Memorial Foundation, 単一T細胞受容体レベルでの機能解析に基づく多発性骨髄腫の新規治療標的の検証
  2. 2024/09, Japanese Society of Hematology Grant-in-aid for Medical Research, Japanese Society of Hematology, 単一T細胞受容体レベルでの機能解析に基づく多発性骨髄腫の新規治療標的の検証
  3. 2019/03, Kyoto University Hospital President's Award, Kyoto University Hospital, Support team for iPS-Parkinson's disease
  4. 2019/02, Grant-in-aid for Medical Research, Uehara Memorial Foundation, Allelic genotyping in allogeneic hematopoietic stem cell transplantation
  5. 2018, Grant-in-aid for Medical Research, The Novartis Foundation for the Promotion of Science, Genotyping of KIR alleles in GVHD after allogeneic hematopoietic stem cell transplantation
  6. 2017/10, Encouragement Award, Japanese Society of Histocompatibility and Immunogenetics, Allelic Polymorphisms of KIRs and HLAs Predict Favorable Responses to Tyrosine Kinase Inhibitors in CML
  7. 2017/06, Kobayashi Foundation for Cancer Research Grant-in-aid for medical research, Kobayashi Foundation for Cancer Research, Optimization of transplant immunity after allogeneic hematopoietic stem cell transplantation
  8. 2017/04, Bristol Myers Squibb Grant-in-aid for Medical Research, Bristol Myers Squibb, Immunomodulation of allogeneic hematopoietic stem cell transplantation focusing on MEK inhibition and KIR polymorphisms
  9. 2016/12, Takeda Science Foundation Grant-in-aid for Medical Research, Takeda Science Foundation, MEK阻害剤を用いた造血幹細胞移植後GVHDの選択的抑制と抗腫瘍免疫の温存
  10. 2016/11, SENSHIN Medical Research Foundation Grant-in-aid for Medical Research, SENSHIN Medical Research Foundation, MEK阻害剤を用いた造血幹細胞移植後免疫抑制の最適化
  11. 2013/11, SENSHIN Medical Research Foundation Grant-in-aid for Medical Research, SENSHIN Medical Research Foundation, MEK阻害剤による移植後GVHDの選択的抑制と感染・腫瘍免疫の温存
  12. 2011/12, American Society of Hematology Abstract Achievement Award, The 53rd annual meeting of the American Society of Hematology
  13. 2011, University of Miami Sylvester Poster Session Best Post-doctoral Fellow, University of Miami Sylvester Comprehensive Cancer Center

External Funds

Acceptance Results of Competitive Funds

  1. Practical Research Project for Allergic Diseases and Immunology (Research on Technology of Medical Transplantation), 2023//8//1, 2024//3//3
  2. Grants-in-Aid for Scientific Research, Optimizing immunity in hematopoietic stem cell transplantation focusing on HLA epitopes, 2023/04, 2026/03
    Permalink
  3. 2022/04/01, 2025/03/31
    Permalink
  4. Optimization of immunosuppressive strategy in solid organ transplantation through HLA epitope typing, 2021/06, 2024/03
    Permalink
  5. Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B), Development of novel biomarkers based on HLA epitopes for organ transplantation and hematopoietic stem cell transplantation, 2021/04, 2024/03
    Permalink
  6. Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Optimizing immunomodulation of hematopoietic stem cell transplantation focusing on allelic polymorphisms of KIRs, 2019/04, 2022/03
    Permalink
  7. Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B), Development of selective immunosuppressive therapy preserving natural immunity for treating chronic rejection after lung transplantation, 2018/04, 2021/03
    Permalink
  8. Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), MEK inhibitors selectively suppress GVHD while sparing antitumor and antiviral immunity after allogeneic hematopoietic stem cell transplantation, 2014/04, 2017/03
    Permalink